Factors affecting serum concentrations of hepatitis C virus (HCV) RNA in HCV genotype 1-infected patients with chronic hepatitis

Research output: Contribution to journalArticle

Abstract

The serum concentration of hepatitis C virus (HCV) RNA is usually stable (4 to 8 log10 IU/ml) in untreated patients with chronic hepatitis C. While this baseline HCV RNA concentration ([HCV RNA]BL) is predictive of a sustained virologic response to treatment, its determinants are only partially identified. We therefore analyzed the baseline characteristics of 2,472 HCV genotype 1-infected patients to identify correlations with gender, age, race, weight, body mass index (BMI), HCV acquisition mode, HCV subtype, alanine aminotrans-ferase concentration, or histopathologic changes in the liver. After separation of the data according to four [HCV RNA]BL groups (≤5.0, >5.0 to 5.6, >5.6 to 5.9, and >5.9 log10 IU/ml), we determined that increasing [HCV RNA]BL correlated (P <0.05) with increasing proportions of patients who were male, >40 years of age, or heavier (a weight of >85 kg or a BMI of >27 kg/m2). Histologic activity index (HAI) data were available for 1,304 of these patients: increasing [HCV RNA]BL correlated with higher fibrosis and necrosis-inflammation scores. As a continuous variable, [HCV RNA]BL correlated with age, gender, weight (continuous or ≤85 versus >85 kg), BMI (continuous or ≤27 versus >27 kg/m2), subtype, fibrosis score, and necrosis-inflammation score; however, multiple-regression analysis yielded P values of 27 kg/m 2), and fibrosis score. While our findings are suggestive of a role for these factors in maintenance of the pretreatment state of HCV infection, the multiple-regression model accounted for only ≤4.6% of the [HCV RNA] BL differences between individuals (R2 = 0.046 for 1,304 patients with HAI scores; 0.043 for all 2,472 patients).

Original languageEnglish (US)
Pages (from-to)2426-2433
Number of pages8
JournalJournal of Clinical Microbiology
Volume45
Issue number8
DOIs
StatePublished - Aug 2007

Fingerprint

Chronic Hepatitis
Hepacivirus
Genotype
RNA
Serum
Body Mass Index
Fibrosis
Weights and Measures
Necrosis
Inflammation
Chronic Hepatitis C
Virus Diseases
Individuality
Alanine
Regression Analysis
Maintenance

ASJC Scopus subject areas

  • Microbiology (medical)
  • Microbiology

Cite this

@article{58c527d7c9ad43ddbc276afafd935732,
title = "Factors affecting serum concentrations of hepatitis C virus (HCV) RNA in HCV genotype 1-infected patients with chronic hepatitis",
abstract = "The serum concentration of hepatitis C virus (HCV) RNA is usually stable (4 to 8 log10 IU/ml) in untreated patients with chronic hepatitis C. While this baseline HCV RNA concentration ([HCV RNA]BL) is predictive of a sustained virologic response to treatment, its determinants are only partially identified. We therefore analyzed the baseline characteristics of 2,472 HCV genotype 1-infected patients to identify correlations with gender, age, race, weight, body mass index (BMI), HCV acquisition mode, HCV subtype, alanine aminotrans-ferase concentration, or histopathologic changes in the liver. After separation of the data according to four [HCV RNA]BL groups (≤5.0, >5.0 to 5.6, >5.6 to 5.9, and >5.9 log10 IU/ml), we determined that increasing [HCV RNA]BL correlated (P <0.05) with increasing proportions of patients who were male, >40 years of age, or heavier (a weight of >85 kg or a BMI of >27 kg/m2). Histologic activity index (HAI) data were available for 1,304 of these patients: increasing [HCV RNA]BL correlated with higher fibrosis and necrosis-inflammation scores. As a continuous variable, [HCV RNA]BL correlated with age, gender, weight (continuous or ≤85 versus >85 kg), BMI (continuous or ≤27 versus >27 kg/m2), subtype, fibrosis score, and necrosis-inflammation score; however, multiple-regression analysis yielded P values of 27 kg/m 2), and fibrosis score. While our findings are suggestive of a role for these factors in maintenance of the pretreatment state of HCV infection, the multiple-regression model accounted for only ≤4.6{\%} of the [HCV RNA] BL differences between individuals (R2 = 0.046 for 1,304 patients with HAI scores; 0.043 for all 2,472 patients).",
author = "Ticehurst, {John R} and Hamzeh, {Fayez M.} and Thomas, {David L}",
year = "2007",
month = "8",
doi = "10.1128/JCM.02448-06",
language = "English (US)",
volume = "45",
pages = "2426--2433",
journal = "Journal of Clinical Microbiology",
issn = "0095-1137",
publisher = "American Society for Microbiology",
number = "8",

}

TY - JOUR

T1 - Factors affecting serum concentrations of hepatitis C virus (HCV) RNA in HCV genotype 1-infected patients with chronic hepatitis

AU - Ticehurst, John R

AU - Hamzeh, Fayez M.

AU - Thomas, David L

PY - 2007/8

Y1 - 2007/8

N2 - The serum concentration of hepatitis C virus (HCV) RNA is usually stable (4 to 8 log10 IU/ml) in untreated patients with chronic hepatitis C. While this baseline HCV RNA concentration ([HCV RNA]BL) is predictive of a sustained virologic response to treatment, its determinants are only partially identified. We therefore analyzed the baseline characteristics of 2,472 HCV genotype 1-infected patients to identify correlations with gender, age, race, weight, body mass index (BMI), HCV acquisition mode, HCV subtype, alanine aminotrans-ferase concentration, or histopathologic changes in the liver. After separation of the data according to four [HCV RNA]BL groups (≤5.0, >5.0 to 5.6, >5.6 to 5.9, and >5.9 log10 IU/ml), we determined that increasing [HCV RNA]BL correlated (P <0.05) with increasing proportions of patients who were male, >40 years of age, or heavier (a weight of >85 kg or a BMI of >27 kg/m2). Histologic activity index (HAI) data were available for 1,304 of these patients: increasing [HCV RNA]BL correlated with higher fibrosis and necrosis-inflammation scores. As a continuous variable, [HCV RNA]BL correlated with age, gender, weight (continuous or ≤85 versus >85 kg), BMI (continuous or ≤27 versus >27 kg/m2), subtype, fibrosis score, and necrosis-inflammation score; however, multiple-regression analysis yielded P values of 27 kg/m 2), and fibrosis score. While our findings are suggestive of a role for these factors in maintenance of the pretreatment state of HCV infection, the multiple-regression model accounted for only ≤4.6% of the [HCV RNA] BL differences between individuals (R2 = 0.046 for 1,304 patients with HAI scores; 0.043 for all 2,472 patients).

AB - The serum concentration of hepatitis C virus (HCV) RNA is usually stable (4 to 8 log10 IU/ml) in untreated patients with chronic hepatitis C. While this baseline HCV RNA concentration ([HCV RNA]BL) is predictive of a sustained virologic response to treatment, its determinants are only partially identified. We therefore analyzed the baseline characteristics of 2,472 HCV genotype 1-infected patients to identify correlations with gender, age, race, weight, body mass index (BMI), HCV acquisition mode, HCV subtype, alanine aminotrans-ferase concentration, or histopathologic changes in the liver. After separation of the data according to four [HCV RNA]BL groups (≤5.0, >5.0 to 5.6, >5.6 to 5.9, and >5.9 log10 IU/ml), we determined that increasing [HCV RNA]BL correlated (P <0.05) with increasing proportions of patients who were male, >40 years of age, or heavier (a weight of >85 kg or a BMI of >27 kg/m2). Histologic activity index (HAI) data were available for 1,304 of these patients: increasing [HCV RNA]BL correlated with higher fibrosis and necrosis-inflammation scores. As a continuous variable, [HCV RNA]BL correlated with age, gender, weight (continuous or ≤85 versus >85 kg), BMI (continuous or ≤27 versus >27 kg/m2), subtype, fibrosis score, and necrosis-inflammation score; however, multiple-regression analysis yielded P values of 27 kg/m 2), and fibrosis score. While our findings are suggestive of a role for these factors in maintenance of the pretreatment state of HCV infection, the multiple-regression model accounted for only ≤4.6% of the [HCV RNA] BL differences between individuals (R2 = 0.046 for 1,304 patients with HAI scores; 0.043 for all 2,472 patients).

UR - http://www.scopus.com/inward/record.url?scp=34548081220&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548081220&partnerID=8YFLogxK

U2 - 10.1128/JCM.02448-06

DO - 10.1128/JCM.02448-06

M3 - Article

VL - 45

SP - 2426

EP - 2433

JO - Journal of Clinical Microbiology

JF - Journal of Clinical Microbiology

SN - 0095-1137

IS - 8

ER -